Questions around this news
What did the unbuzzd trial report?
The release says the study found significantly lower estimated blood alcohol concentrations, along with improved self-rated alertness and reduced headache severity among participants. It characterizes the findings as early and notes that Men’s Fitness described them as promising; it does not provide further study details in the release excerpt.
What is unbuzzd designed to do?
The release describes unbuzzd as a supplement drink designed to support alcohol metabolism. It says Quantum BioPharma invented the drink and retains royalty and equity interests in the consumer brand.
Why does testing a recovery drink against a placebo matter?
A placebo comparison helps researchers assess whether reported effects are associated with the product rather than expectations or other factors. In a registered human trial, researchers study an intervention in people under a defined protocol, with the study recorded in a public registry.
What does estimated blood alcohol concentration indicate?
Estimated blood alcohol concentration is an approximation of the amount of alcohol in a person’s blood. It may be derived from measurements or other information, and is distinct from a direct laboratory measurement of blood alcohol.
- Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as “promising.”
- Results showed that estimated blood alcohol concentration was significantly lower and participants experienced improved self-rated alertness and lower headache severity.
- For operators in this space, the stakes reach beyond the morning after.
Most recovery drinks promise relief after a night out, yet few have been tested against a placebo in a registered human trial. One that has is now getting a close look from a major fitness publication. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders, has invented unbuzzd, a supplement drink designed to support alcohol metabolism, and keeps royalty and equity interests in the consumer brand.
Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as “promising.” The magazine notes that “a small clinical trial found improvements in alcohol readings, alertness, and headache symptoms . . . [offering] early encouragement. Researchers reported lower estimated blood alcohol concentrations at several time…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Terms explained
- Placebo
- A substance or treatment made to resemble the one being studied but lacking its active ingredient, used as a comparison in research.
- Clinical trial
- A research study involving people that evaluates an intervention, such as a drug, supplement, or medical procedure.
- Estimated blood alcohol concentration
- An approximation of the proportion of alcohol in a person’s blood, based on measurements or other information.
- Alcohol metabolism
- The processes by which the body breaks down and removes alcohol.
- Self-rated alertness
- A participant’s own assessment of how awake or attentive they feel.
SEC filings
Earlier from Quantum BioPharma
- Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
- Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
- Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
- Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
- Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
